Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals’ EBV (Epstein Barr Virus) Vaccine (268664).

This study has been completed.
Sponsor:
Information provided by:
Henogen
ClinicalTrials.gov Identifier:
NCT00430534
First received: February 1, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given
No publications provided by Henogen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):